ІМУНОГІСТОХІМІЧНЕ ДОСЛІДЖЕННЯ ДЕФЕКТІВ СИСТЕМИ РЕПАРАЦІЇ ТА ЗВ’ЯЗКУ ЇХ ІЗ КЛІНІЧНИМ ПЕРЕБІГОМ ГЛІОБЛАСТОМИ У ХВОРИХ БРАЗИЛІЇ

• Date: 2023
• Main Authors: Yamada, C.A.F., Malheiros, S.M.F., do Amaral, L.L.F., Lancellotti, C.L.P.
• Format: Article
• Language: English
• Published: PH Akademperiodyka 2023
• Subjects: пухлини головного мозку; гліобластома; гліома; мікросателітна нестабільність; репарація неспарених основ
• Online Access: https://exp-oncology.com.ua/index.php/Exp/article/view/2023-3-297
• Journal Title: Experimental Oncology

Background. Glioblastoma (GBM) is the most frequent primary malignant CNS tumor. Deficient mismatch repair (dMMR) is associated with better prognosis and is a biomarker for immunotherapy. Evaluation of MMR by immunohistochemistry (IHC) is accessible, cost effective, sensitive, and specific. Aim. Our objective was to investigate MMR proteins in adult GBM patients. Materials and Methods. We retrospectively analyzed 68 GBM samples to evaluate the proficiency of MMR genes expression assessed by IHC. Clinicopathologic and molecular features were compared in proficient (pMMR) or dMMR. Results. 10 (14.7%) samples showed dMMR, and the most frequent was MSH6 (100%) followed by MSH2, PMS2, and MLH1. We observed heterogeneous expression of dMMR in 5 GBMs. The median overall survival did not differ between pMMR (19.8 months; 0.2—30) and dMMR (16.9 months; 6.4—27.5) (p = 0.31). We observed a significantly higher overall survival associated with gross total resection compared to subtotal resection or biopsy (30.7 vs. 13.6 months, p = 0.02) and MGMT methylated status (29.6 vs. 19.8 months, p = 0.049). At the analysis time, 10 patients were still alive, all in the pMMR group. Conclusions. Our data demonstrated dMMR phenotype assessed by IHC in an expressive portion of GBM patients, however without significant impact on overall survival.